Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current Medical Research and Opinion

• Publication date

  2013-08-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1185/03007995.2013.837817PMID 23971789
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial

  2013cited by this paper
• Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

  2013cited by this paper
• Incretin Therapy and Islet Pathology: A Time for Caution

  2013cited by this paper
• We've come a long way…haven't we?

  2013cited by this paper
• Canadian Diabetes Association Clinical Practice Guidelines Expert Committee

  2013cited by this paper
• Pharmacologic management of type 2 diabetes.

  2013cited by this paper
• Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes

  2013cited by this paper
• Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%.

  2013cited by this paper
• A Retrospective Audit of Type 2 Diabetes Patients Prescribed Liraglutide in Real-Life Clinical Practice

  2013cited by this paper
• Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors

  2013cited by this paper
• Glucagonlike Peptide 1-based drugs and pancreatitis: clarity at last, but what about pancreatic cancer?

  2013cited by this paper
• A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice

  2012cited by this paper
• Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials

  2012cited by this paper
• Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes

  2012cited by this paper
• β-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy

  2012cited by this paper
• Recent advances in incretin‐based therapies

  2012cited by this paper
• Exenatide plus metformin compared with metformin alone on β‐cell function in patients with Type 2 diabetes

  2012cited by this paper
• Effectiveness of a diabetes education and self management programme (DESMOND) for people with newly diagnosed type 2 diabetes mellitus: three year follow-up of a cluster randomised controlled trial in primary care

  2012cited by this paper
• Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy

  2012cited by this paper
• Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population

  2012cited by this paper
• Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.

  2012cited by this paper
• Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta‐analysis of the liraglutide clinical trial programme

  2012cited by this paper
• Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide inMonotherapy A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)

  2012cited by this paper
• RECOMMANDATIONS 2012 EN DIABÉTOLOGIE: Prise en charge de l'hyperglycémie dans le diabète de type 2: une approche centrée sur le patient

  2012cited by this paper
• Identifying Predictors of Response to Liraglutide in Type 2 Diabetes Using Recursive Partitioning Analysis

  2012cited by this paper
• Effects of a 6-Month Exenatide Therapy on HbA1c and Weight in Korean Patients with Type 2 Diabetes: A Retrospective Cohort Study

  2012cited by this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cited by this paper
• Obesity – an indication for GLP‐1 treatment? Obesity pathophysiology and GLP‐1 treatment potential

  2011cited by this paper
• Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies

  2011cited by this paper
• Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

  2011cited by this paper
• Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.

  2011cited by this paper
• Fifty‐two‐week, randomized, multicenter trial to compare the safety and efficacy of the novel glucagon‐like peptide‐1 analog liraglutide vs glibenclamide in patients with type 2 diabetes

  2011cited by this paper
• Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients.

  2011cited by this paper
• Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting

  2011cited by this paper
• Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

  2011cited by this paper
• Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes

  2011cited by this paper
• One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial

  2011cited by this paper
• Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

  2010cited by this paper
• Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin

  2010cited by this paper
• Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.

  2010cited by this paper
• Clinical inertia in patients with T2DM requiring insulin in family practice.

  2010cited by this paper
• Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada.

  2010cited by this paper
• Incretin agents in type 2 diabetes.

  2010cited by this paper
• Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

  2010cited by this paper
• Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies

  2010cited by this paper
• Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes

  2010cited by this paper
• Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis

  2010cited by this paper
• Global estimates of the prevalence of diabetes for 2010 and 2030.

  2010cited by this paper
• Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

  2009cited by this paper
• Six‐month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting

  2009cited by this paper
• Secondary Failure of Metformin Monotherapy in Clinical Practice

  2009cited by this paper
• Standards of medical care in diabetes--2007.

  2009cited by this paper
• One-Year Treatment With Exenatide Improves β-Cell Function, Compared With Insulin Glargine, in Metformin-Treated Type 2 Diabetic Patients

  2009cited by this paper
• Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.

  2009cited by this paper
• Standards of Medical Care in Diabetes—2009

  2009cited by this paper
• Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily1

  2009cited by this paper
• Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

  2009cited by this paper
• Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

  2009cited by this paper
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

  2009cited by this paper
• 10-year follow-up of intensive glucose control in type 2 diabetes.

  2008cited by this paper
• Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

  2008cited by this paper
• Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

  2008cited by this paper
• DIABETICMedicine Blackwell Publishing Ltd Original Article: Complications DOI: 10.1111/j.1464-5491.2009.02667.x Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor

  2008cited by this paper
• Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care

  2007cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study

  2004cited by this paper
• The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

  2003cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)

  1999cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

  1993cited by this paper
• Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group.

  1993cited by this paper
• Pancreatitis and the risk of pancreatic cancer.

  1993cited by this paper
• Oral antidiabetic combination therapy with sulphonylureas and metformin.

  1991cited by this paper
• Diarrhea and Metformin in a Diabetic Clinic

  1983cited by this paper
• CARDIO VASCULAR DIABETOLOGY ORIGINAL INVESTIGATION Open Access Cardiovascular safety of exenatide BID: an

  year unknowncited by this paper

• Use of second-line diabetes mellitus medications among older adults after the introduction of GLP-1 receptor agonists in Ontario, Canada: a retrospective cohort study.

  2025cites this paper
• Achievement of HbA1c and weight targets in adults with type 2 diabetes on once weekly injectable glucagon‐like peptide‐1 receptor agonist therapy in UK primary care: A retrospective, real‐world study

  2025cites this paper
• Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57)

  2020cites this paper
• Activation of pCREB/Nrf-2 signaling mediates re-positioning of liraglutide as hepato-protective for methotrexate -induced liver injury (MILI).

  2019cites this paper
• The Effect of Early Response to GLP-1 RA Therapy on Long-Term Adherence and Persistence Among Type 2 Diabetes Patients in the United States.

  2019cites this paper
• Complement 1q-like-3 protein inhibits insulin secretion from pancreatic β-cells via the cell adhesion G protein–coupled receptor BAI3

  2018cites this paper
• Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes.

  2017cites this paper
• Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide

  2017cites this paper
• Targeting beta-cell preservation in the management of type 2 diabetes

  2017cites this paper
• Brief review A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes

  2015cites this paper
• Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN‐J)

  2015cites this paper
• A multiplicity of targets: evaluating composite endpoint studies of the GLP-1 receptor agonists in type 2 diabetes

  2015cites this paper
• Agonistes du récepteur du GLP-1 en une injection hebdomadaire : quelles perspectives pour le patient diabétique de type 2 ?

  2014cites this paper
• Efficacy of Liraglutide in a Real-Life Cohort

  2014cites this paper
• Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus

  2014cites this paper